The perturbations of the cytokine signaling pathway play an important role in lymphoid/hematopoietic tumors. Aberrant promoter methylation is the major mechanism of gene silencing in tumors. We examined 150 lymphoid/ hematopoietic tumors or potential premalignant specimens, 55 control specimens and 12 EBV-transformed B lymphoblastoid cultures and 10 lymphoma/leukemia (L/L) or multiple myeloma (MM) cell lines for the methylation (and, in cell lines, of the expression status) of three genes involved in the cytokine signaling pathway. The genes were: SHP1, a protein tyrosine phosphatase; SYK, a protein kinase; and SOCS1, a suppressor of cytokine signaling. Our major findings were: (1) one or more of the three genes was frequently methylated in L/L and MM cell lines and there was good concordance (90-100%) between methylation and loss of gene expression; (2) treatment of L/L cell lines with a demethylating agent resulted in re-expression of SHP1 protein and downregulation of phosphorylated STAT3 in L/L cell lines; (3) all 55 control specimens and the lymphoblastoid cultures were negative for methylation of the three genes; (4) nonHodgkin's lymphomas (100%), and leukemias (94%) had almost universal methylation of SHP1 and relatively less frequent (o30%) methylation of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had infrequent methylation of SHP1 (o20%), and occasional methylation of SOCS1 and SYK; and (6) comparable methylation frequencies for SOCS1 were observed in MM and MGUS, suggesting that SOCS1 methylation is an early event in MM pathogenesis. At least one gene was methylated in 119 of 130 (93%) of the malignant and 12 of 20 (60%) of the MGUS samples. Our findings demonstrate that the perturbations of cytokine signaling via silencing of these three genes are almost universal in lymphoid/hematopoietic tumors but the patterns of gene methylated for L/L and plasma cell dyscrasias are different.
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The JAK/STAT signal transduction pathway is an important intracellular signaling mechanism activated by various cytokines and growth factors (O' Shea et al., 2002; Wu et al., 2003) . Upregulation of STAT proteins (especially STAT3 and STAT5) is related to decreased apoptosis and increased cell proliferation, events that promote tumorigenesis (Bowman et al., 2000; Bromberg, 2002) .
Inactivation of genes may occur via point mutations, allelic losses and homozygous deletions or by aberrant methylation. Aberrant methylation of 5 0 gene promoter regions associated with gene silencing is an epigenetic phenomenon involving many genes and is observed in almost all cancer types. Aberrant promoter methylation of CpG-rich areas of promoter regions (along with the related epigenetic phenomenon of histone deacetylation) is the most frequent mechanism of tumor suppressor gene silencing in human tumors (Jones and Baylin, 2002) . Three genes that regulate cytokine signaling, SHP1 (12p13-22), SOCS1 (16p12-13) and SYK (9q22), are inactivated through hypermethylation of their promoters in certain tumor types (Yoshikawa et al., 2001; Yuan et al., 2001; Oka et al., 2002) . These genes are frequently methylated in lymphomas and leukemias (SHP1) (Oka et al., 2002; Chim et al., 2004) , MMs (SOCS1) (Chim et al., 2004; Galm et al., 2003) and Tcell leukemias (SYK) (Goodman et al., 2003) . In this report we investigated simultaneously, for the first time, the methylation status of all three cytokine regulators in a wide range of leukemias, lymphomas and PCDs including MGUS cases.
Peripheral blood mononuclear cells (PBMCs) were obtained from 14 healthy volunteers. Other controls (n ¼ 41) and L/L samples (n ¼ 90) were obtained from the Flow Cytometry Facility or the Department of Pathology at the UT Southwestern Medical Center, Dallas, TX and its affiliated hospitals, after receiving Institutional Review Board permission. MGUS (n ¼ 20) and MMs (n ¼ 40) were obtained from UT Southwestern Medical Center or University Hospital, Vienna, Austria. Since Hodgkin's disease specimens were not available, our study was limited to non-Hodgkin's lymphomas, leukemias and PCDs. Genomic DNA was extracted from cell lines, primary tumors and nonmalignant cells by using a DNA extraction kit (Serological Corporation, Norcross, GA, USA) (Shivapurkar et al., 2002a) .
In this study, the analyses on cell lines showed that SHP1 was methylated in 70%, SOCS1 in 50% and SYK in 30% of 10 L/L and MM cell lines and there was good concordance (90-100%) for SHP1, SOCS1 and SYK between methylation and loss of gene expression (at RNA level) and with loss of protein expression (by Western blot) for SHP1 and SYK (Figure 1 ). Since the commercially available SOCS1 antibodies yielded nonspecific bands, Western blot analysis for SOCS1 was not carried out. Methylated cell lines were cultured with Figure 1 Methylation-specific PCR (MSP) assay, RT-PCR for SHP1, SOCS1 and SYK and Western blot analyses for SHP1 and SYK in lymphoma (ly) leukemia (le) and MM cell lines. Aberrant promoter methylation of SHP1, SOCS1 and SYK was determined on bisulfite-treated DNA by the method of MSP (Herman et al., 1996) , using primers for methylated sequences and methodologies previously described for SHP1 (Oka et al., 2002) , SOCS1 (Galm et al., 2003) and SYK (Yuan et al., 2001) . MSP assays can detect the presence of one methylated allele in the presence of 10 3 -10 4 unmethylated alleles. Primer sequences specific for the unmethylated form of p16 gene were used to check the integrity of bisulfite-modified DNA. Results were confirmed by repeating bisulfite treatment and MSP for all samples. RNA expressions of SHP1, SYK and SOCS1 were analysed by RT-PCR. Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The RT reactions were performed using SuperScript II (Invitrogen, Carlsbad, CA, USA) and Hot Star Taq DNA Polymerase (Qiagen Inc., Valencia, CA, USA) and genespecific primers (Yuan et al., 2001; Oka et al., 2002; Galm et al., 2003) . Western blot analyses for protein expression were performed essentially as described previously (Shivapurkar et al., 2002b, c) . Primary antibodies against SHP1 and SYK were from Santa Cruz Biotech, Santa Cruz, CA, USA and the secondary antibody was from Amersham, Piscataway, NJ, USA. A total of 22 cell lines were used; 15 of them were initiated by us of which 12 were Epstein-Barr virus-transformed lymphoblastoid B-cell (BL) lines from the PBMCs of healthy individuals that had been in continuous culture for about 5 months when tested, and three were lymphohematopoietic malignancies, lymphomas (HCC 3234, Hut 78) or MM (NCI-H929). The other seven cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) lymphomas (BC-1, BC-3, RL), leukemias (Jurkat, K-562) and MM (U266B1, MC/CAR). The housekeeping genes GAPDH and actin were used as controls for integrity of RNA and protein loading, respectively. The controls were as follows: (a) MSP-positive control, DNA from a methylation-positive lung cancer cell line (methylation confirmed through sequencing); (b) negative control, water blank; (c) protein, known positive cell lysate used as positive control (BJAB for SYK and Jurkat for SHP1) (data not shown); (d) we also used peripheral blood lymphocytes (NL) from healthy donor as a control for all the assays. PCR products were visualized on 2% agarose gels stained with ethidium bromide. Protein lysates were electrophoresed on 7.5% SDS-polyacrylamide gel Cytokine signaling in lympho-hematopoietic tumors J Reddy et al 5-Aza-CdR at a concentration of 4 mM for 6 days, with medium changes on days 1, 3 and 5, to check for restoration of gene expression. SHP1 (n ¼ 7) and SOCS1 (n ¼ 5) gene expression was restored in all cell lines and SYK was restored in four of the five cell lines tested. Sequencing of five independent plasmid clones of bisulfite-treated DNA (Oka et al., 2002; Galm et al., 2003) confirmed that methylation was almost uniform in promoter region CpG sites in expression-negative cell lines and absent in expression-positive lines. Thus, epigenetic inactivation of these genes appears to be the predominant cause of gene silencing. We examined specimens (PBMC, lymph nodes, bone marrows) from three different control groups: (1) healthy volunteers (n ¼ 14); (2) hematological patients without malignancy (n ¼ 12) and (3) hematological malignancy patients in remission (n ¼ 29). We also analysed 12 lymphoblastoid B-cell (BL) lines, which were positive for expression but negative for methylation for all the three genes ( Figure 1) .
Further, to demonstrate that promoter methylation of the genes results in loss of their expression at protein level (and also results in upregulation of the JAK-STAT pathway), we analysed LL samples for SHP1 methylation, SHP1 protein expression and phosphorylated STAT3 (Figure 3a) . Two B-cell lymphomas and one CLL specimen having more than 80% tumor cells (as determined by flow cytometry) were available. Such tumor samples with high tumor cell percentage were expected to minimize the effect due to nonmalignant cells in the samples. All three tumor samples were methylated with downregulation of SHP1 and upregulation of the phosphorylated form of STAT3 compared to control samples (BL cell lines and PBMC from healthy volunteers). We also treated three cell lines (one each of lymphoma, leukemia and MM) lacking SHP1 protein expression with 5-Aza-CdR (Figure 3b ). We observed that 5-Aza-CdR treatment resulted in reexpression of SHP1 protein and downregulation of phosphorylated STAT3 in the lymphoma and the leukemia cell lines. 5-Aza-CdR treatment resulted in weak re-expression of SHP1 protein in the MM cell line but phosphorylated STAT3 was not detected. Our data confirm that SHP1 methylation is associated with downregulation of its protein product and upregulation of the JAK-STAT pathway. In addition, they confirm that there are important differences in JAK/STAT regulation between L/L and MM.
For the three genes analysed in the tumors, the differences between L/L and between MMs and MGUS cases were either not significant or of marginal significance. Thus, we compared the combined groups of L/L with MM/MGUS cases. The L/L group was significantly more associated with SHP1 methylation, which was present in 97% of samples (100% of lymphomas and 94% of leukemias). SHP1 methylation was significantly (Po0.0001) lower in PCDs (15% of MM and 20% of MGUS) (Figure 2 ). Flow cytometric determination of tumor cell percentage was available for 87 of the malignant samples (25 lymphomas, 37 leukemias and 25 PCDs). SHP1 methylation was present in 64 of these cases, and their tumor cell percentages had a mean value of 49% (range 1-98%). SHP1 methylation was absent in 23 cases, and their tumor cell percentages had a mean value of 56% (range 1-90%). Methylation of the other two genes was noted in smaller subgroups of the major tumor divisions. However, the frequencies of methylation were different for L/L compared to PCD, more so for SYK than for SOCS1 (Figure 2 ). SOCS1 methylation was significantly more frequent in PCDs (40% of MM and 45% of MGUS) and significantly low (21%, Po0.02) in the L/L group. SYK methylation was relatively low (6%) in the L/L group (10% of lymphomas and 2% of leukemias) and significantly higher (28%, Po0.0007) in the PCDs (38% of MM and 20% of MGUS). At least one of the three genes was methylated in 119 of 130 (93%) of the malignant, including 32 of 40 (80%) of MM cases and 12 of 20 (60%) of the MGUS samples. Surprisingly, the methylation frequencies between MM and MGUS were not significantly different (Figure 2b ). Of interest, in PCDs, methylation of SOCS1 was negatively associated with methylation of SYK (Po0.008), suggesting that . The frequencies of methylation between groups were compared using the w 2 test. Association between the genes was examined using contingency tables and Fisher's exact probability tests. P-values o0.05 were considered significant Cytokine signaling in lympho-hematopoietic tumors J Reddy et al only one of the genes needs to be silenced in these tumors (Figure 2) . We tested all the L/L cases for the presence of Epstein-Barr virus (EBV) using a real-time PCR assay (Jebbink et al., 2003) . EBV-positive cases were limited only to lymphomas. The methylation patterns of the EBV-positive and -negative lymphoma cases were identical, and all cases had SHP1 methylation. Peripheral blood B lymphocytes can be transformed in vitro on exposure to EBV. The resultant lymphoblastoid cultures express a limited set of viral latent proteins (Young and Murray, 2003) . We found that all 12 B lymphoblastoid cultures tested lacked methylation of all the three cytokine genes. Thus, the cytokine signaling pathways of B lymphoblastoid cultures appear to be very different from those of EBV-transformed lymphomas. Since MGUS is believed to be a premalignant lesion with potential for progression to malignancy, our results suggest that epigenetic inactivation of SOCS1 may be an early event in MM pathogenesis and the role of SOCS1 in the earlier stages of MM pathogenesis should be further explored. Previous molecular studies in MM have largely focused on genetic aberrations of MM (Kuehl and Bergsagel, 2002) . The methylation status of only p15 and p16 genes has been reported in MGUS (Guillerm et al., 2001) . Our study finds SOCS1 methylation in 40% of MMs and 45% of MGUS. Thus, the methylated forms of these genes should be further explored as a panel of markers for early detection of MGUS cases more likely to transform to MM.
Upregulation of JAK/STAT signaling is frequent in hematopoietic and other malignancies and may occur via upregulation of cytokines such as IL6 or by inhibition of negative regulators of the pathway. SHP1 is a cytoplasmic tyrosine phosphatase containing two amino-terminal SH2 domains followed by a phosphatase domain. It is a negative regulator of cytokine signaling by binding to and dephosphorylating JAKs (Yasukawa et al., 2000; Wu et al., 2003) . SOCS1 belongs to a family of cytoplasmic proteins that contain a central SH2 domain and a carboxy-terminal 'SOCS' box (Krebs and Hilton, 2000) . SOCS1 can disrupt cytokine signaling by binding to JAKs and inhibiting their catalytic activity. The role of SYK in JAK/STAT regulation is less well characterized. SYK and the related protein ZAP-70 comprise a family of nonreceptor tyrosine kinases expressed in most hematopoietic cells that play a role in signal transduction by T-and B-cell antigen and other receptors (Turner et al., 2000) . They contain tandem SH2 domains, which, upon phosphorylation, can bind to the SH2 domains of other molecules. SHP1 can bind to SYK and form a multiprotein signaling complex (Ganju et al., 2000) .
While there are many subtypes of leukemias and lymphomas having major differences in their clinical course and molecular origins, we did not detect significant differences between the major groups (lymphoid versus myeloid leukemias, acute versus chronic leukemias, high-grade versus low-grade lymphomas, Bcell versus T-cell lymphomas). However, the pattern of methylation between the combined LL group and MM was significantly different. While in both groups at least one of the genes was methylated in 80-100%, SHP1 methylation was almost universal in LL while in MM no single gene appeared to play a dominant role. Also, in MM, there was a negative correlation between methylation of SOCS1 and SYK, a finding not noted in LLs. MM, a disease of antibody-producing B cells, has distinct features including formation of osteolytic lesions, being relatively resistant to therapy and having a high fatality rate. Our findings provide further evidence that MM differs from other hematologic malignancies.
In summary, we demonstrate for the first time that perturbations of cytokine signaling via epigenetic inactivation of SHP1, SOCS1 and SYK are almost universal in lymphoid/hematopoietic tumors but that PCDs utilize a pathway strikingly different from other lymphoid/hematopoietic malignancies. Methylation of SHP1 is both a sensitive and specific test for leukemias and lymphomas, suggesting that it may be useful for diagnosis and detection of minimal residual disease. SOCS1 may be a unique early marker for MM. Western blot analyses for protein expression were performed essentially as described in Figure 1 . The figure shows re-expression of SHP1 in all three cell lines and downregulation of phosphorylated STAT3 in BC3 and U26B1 but no change in K-562
